Fresenius
Fresenius SE & Co. KGaA, commonly referred to as Fresenius, is a global healthcare group headquartered in Bad Homburg, Germany. Founded in 1912, the company has established itself as a leader in the healthcare industry, with significant operations across Europe, North America, and Asia. Fresenius operates primarily in the fields of dialysis, hospital management, and medical devices, providing innovative solutions that enhance patient care. The company’s core offerings include dialysis products and services through Fresenius Medical Care, as well as pharmaceuticals and clinical nutrition via Fresenius Kabi. Known for its commitment to quality and patient-centric solutions, Fresenius has achieved notable milestones, including being a key player in the global dialysis market. With a strong market position and a reputation for excellence, Fresenius continues to drive advancements in healthcare, making a meaningful impact on patients' lives worldwide.
DitchCarbon Score
How does Fresenius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius's score of 63 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius's reported carbon emissions
In 2024, Fresenius reported total carbon emissions of approximately 4,000,000,000 kg CO2e, comprising 351,128,000 kg CO2e from Scope 1, 164,838,000 kg CO2e from Scope 2 (market-based), and a significant 3,683,377,000 kg CO2e from Scope 3 emissions. This reflects a continued commitment to reducing its carbon footprint, with a target to achieve climate neutrality by 2040 and a 50% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. In 2023, the company reported 344,161,000 kg CO2e in Scope 1 and 215,434,000 kg CO2e in Scope 2 emissions (market-based), indicating a slight increase in emissions compared to previous years. The 2022 data showed 315,000,000 kg CO2e for Scope 1 and 326,000,000 kg CO2e for Scope 2 (market-based), highlighting the challenges in emission reductions. Fresenius Medical Care, a subsidiary, has set ambitious near-term goals to reduce its Scope 1 and Scope 2 emissions to near zero by 2025, further underscoring the group's commitment to sustainability. The company is also aiming for a 30% reduction in Scope 1 and Scope 2 emissions by 2030 from a 2020 baseline. Overall, Fresenius's climate strategy is robust, with clear targets and a focus on significant emission reductions across all scopes, aligning with global climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
